Fig. 1: Cumulative incidence of CEs over time, per arm of treatment. | British Journal of Cancer

Fig. 1: Cumulative incidence of CEs over time, per arm of treatment.

From: Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Fig. 1

There is a non-statistical difference of −1.4% in the rate of CE on T + L arm (7.9%) vs T arm (9.3%), with a multivariate OR of 0.85 [(95% CI, 0.68–1.05); p = 0.139]. The rates of CEs at the 6th month are 4.1% and 4.7% on T + L arm and T arm, respectively, increasing to 6.1% and 7.8% at the 12th month, and to a lesser extent to 6.6% and 8.2% at the 18th month, respectively.

Back to article page